Live Breaking News & Updates on Alkermes Pharma Ireland Limited

Stay updated with breaking news from Alkermes pharma ireland limited. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Alkermes plc: Alkermes Commences Arbitration Related to License Agreements with Janssen Pharmaceutica

DUBLIN, April 19, 2022 /PRNewswire/ Alkermes plc (Nasdaq: ALKS) today announced that it commenced binding arbitration proceedings in respect of two license agreements with Janssen Pharmaceutica ....

United States , Katie Joyce , Sandy Coombs , Johnson Corporation , Exchange Commission , Institute For Conflict Prevention , Alkermes Inc , Alkermes Pharma Ireland , Conflict Prevention , Non Administered Arbitration , Private Securities Litigation Reform Act , Annual Report , Alkermes Pharma Ireland Limited , Viiv Healthcare United Kingdom ,

Alkermes Presents New Data From Psychiatry Portfolio at 2022 Congress of the Schizophrenia International Research Society

/PRNewswire/ Alkermes plc (Nasdaq: ALKS) today presented new research from its psychiatry portfolio at the 2022 Congress of the Schizophrenia International. ....

New York , United States , Alex Braun , Craig Hopkinson , Marisa Borgasano , Aripiprazole Lauroxil , Behavioral Health System , Research Databases , Schizophrenia International Research Society , Research Development At Alkermes , Department Of Psychiatry , Icahn School Of Medicine At Mount Sinai , Alkermes Inc , Alkermes Pharma Ireland , Detailed Results Presented From , Early Phase , Patients Early , New York Assessment , Adverse Cognitive Effects , Neuropsychiatric Treatment , Chief Medical Officer , Executive Vice President , Young Adults , Schizophreniform Disorder , Bipolari Disorder Who Are Early , Their Illness ,

Alkermes plc: Alkermes Presents New Data From Psychiatry Portfolio at 2022 Congress of the Schizophrenia International Research Society

- Detailed Results Presented From ENLIGHTEN-Early Phase 3b Study of LYBALVI in Patients Early in Illness - DUBLIN, April 7, 2022 /PRNewswire/ Alkermes plc (Nasdaq: ALKS) today presented ....

New York , United States , Alex Braun , Craig Hopkinson , Marisa Borgasano , Aripiprazole Lauroxil , Behavioral Health System , Research Databases , Schizophrenia International Research Society , Research Development At Alkermes , Department Of Psychiatry , Icahn School Of Medicine At Mount Sinai , Alkermes Inc , Alkermes Pharma Ireland , Results Presented From , Early Phase , Patients Early , New York Assessment , Adverse Cognitive Effects , Neuropsychiatric Treatment , Chief Medical Officer , Executive Vice President , Young Adults , Schizophreniform Disorder , Bipolari Disorder Who Are Early , Their Illness ,

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2021 and Provides Financial Expectations for 2022

Revenues of $1.17 Billion in 2021, GAAP Loss per Share of $0.30 and Diluted Non-GAAP Earnings per Share of $0.78 Financial Expectations for 2022 and Updated Long-Term Profitability ....

United States , Katie Joyce , Iain Brown , Catot Laurencin , Sandy Coombs , Janssen Pharmaceutica , American Society Of Clinical Oncology , Psych Congress , Rodin Therapeutics Inc , Neuroscience Education Institute , Merck Co Inc , Johnson Company , Alkermes Inc , International Society For Affective Disorders , Society For Immunotherapy Of Cancer , Drug Administration , Development Revenues , Merck Sharp Dohme Corp , Exchange Commission , Biogen Ma Inc , Alkermes Pharma Ireland , Proprietary Products , Continued Operating , Richard Pops , Chief Executive Officer , Goods Manufactured ,

Alkermes : Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2021 and Provides Financial Expectations for 2022 - Form 8-K

GAAP Net Loss

-

. | February 16, 2022 ....

United States , Iain Brown , Catot Laurencin , Janssen Pharmaceutica , American Society Of Clinical Oncology , Psych Congress , Rodin Therapeutics Inc , Neuroscience Education Institute , Merck Co Inc , Johnson Company , Alkermes Inc , International Society For Affective Disorders , Society For Immunotherapy Of Cancer , Development Revenues , Merck Sharp Dohme Corp , Exchange Commission , Biogen Ma Inc , Alkermes Pharma Ireland , Reports Financial Results , Fourth Quarter , Year Ended , Provides Financial Expectations , Proprietary Products , Continued Operating Efficiency , Richard Pops , Chief Executive Officer ,